Aparicio Camila, Willis Zachary I, Nakamura Mari M, Wolf Joshua, Little Cordell, Maron Gabriela M, Sue Paul K, Anosike Brenda I, Miller Christine, Bio Laura L, Singh Prachi, James Scott H, Oliveira Carlos R
Department of Pediatrics, Yale University School of Medicine, New Haven, CT.
Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.
medRxiv. 2024 Jan 18:2024.01.17.24301452. doi: 10.1101/2024.01.17.24301452.
Risk stratification is a cornerstone of the Pediatric Infectious Diseases Society COVID-19 treatment guidance. This systematic review and meta-analysis aimed to define the clinical characteristics and comorbidities associated with critical COVID-19 in children and adolescents.
Two independent reviewers screened the literature (Medline and EMBASE) for studies published through August 2023 that reported outcome data on patients aged ≤21 years with COVID-19. Critical disease was defined as an invasive mechanical ventilation requirement, intensive care unit admission, or death. Random effects models were used to estimate pooled odds ratios (OR) with 95% confidence intervals (CI), and heterogeneity was explored through subgroup analyses.
Among 10,178 articles, 136 studies met the inclusion criteria for review. Data from 70 studies, which collectively examined 172,165 children and adolescents with COVID-19, were pooled for meta-analysis. In previously healthy children, the absolute risk of critical disease from COVID-19 was 4% (95% CI, 1%-10%). Compared with no comorbidities, the pooled OR for critical disease was 3.95 (95% CI, 2.78-5.63) for presence of one comorbidity and 9.51 (95% CI, 5.62-16.06) for ≥2 comorbidities. Key risk factors included cardiovascular and neurological disorders, chronic pulmonary conditions (excluding asthma), diabetes, obesity, and immunocompromise, all with statistically significant ORs >2.00.
While the absolute risk for critical COVID-19 in children and adolescents without underlying health conditions is relatively low, the presence of one or more comorbidities was associated with markedly increased risk. These findings support the importance of risk stratification in tailoring pediatric COVID-19 management.
风险分层是美国儿科学会传染病学会COVID-19治疗指南的基石。本系统评价和荟萃分析旨在确定与儿童和青少年重症COVID-19相关的临床特征和合并症。
两名独立评审员筛选了截至2023年8月发表的文献(Medline和EMBASE),以查找报告≤21岁COVID-19患者结局数据的研究。重症疾病定义为需要有创机械通气、入住重症监护病房或死亡。采用随机效应模型估计合并比值比(OR)及95%置信区间(CI),并通过亚组分析探讨异质性。
在10,178篇文章中,136项研究符合纳入标准。汇总了70项研究的数据进行荟萃分析,这些研究共纳入了172,165例COVID-19儿童和青少年。在既往健康的儿童中,COVID-19导致重症疾病的绝对风险为4%(95%CI,1%-10%)。与无合并症相比,合并一种合并症时重症疾病的合并OR为3.95(95%CI,2.78-5.63),合并≥2种合并症时为'9.51(95%CI,5.62-16.06)。主要风险因素包括心血管和神经系统疾病、慢性肺部疾病(不包括哮喘)、糖尿病、肥胖和免疫功能低下,所有这些因素合并OR均>2.00且具有统计学意义。
虽然无基础健康问题的儿童和青少年发生重症COVID-19的绝对风险相对较低,但存在一种或多种合并症会使风险显著增加。这些发现支持了风险分层在制定儿童COVID-19管理方案中的重要性。